Key Insights

Highlights

Treatment Research

3 treatments under study, led by Sirolimus

Related Conditions

Often studied with 16 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 80/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

2Total
P 2 (1)
P 4 (1)

Trial Status

Terminated1
Not Yet Recruiting1
Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT07892651Not Yet RecruitingPrimary

MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)

NCT06722586Phase 4RecruitingPrimary

Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia

NCT02128269Phase 2TerminatedPrimary

Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome

Showing all 3 trials

Research Network

Common Treatments

  • Sirolimus1
  • Placebo1
  • Study Drug Alxn10071

Active Sponsors

  • North China Pharmaceutical Coltd1
  • Peking University First Hospital1
  • Axiom Bioregistry1
  • Alexion Pharmaceuticals Inc1

Related Conditions

  • Membranous Nephropathy1
  • System Lupus Erythematosus1
  • Pompe Disease1
  • Rheumatic Arthritis1
  • Type 1 Diabetes Mellitus1

Activity Timeline